FDA Review Modernization

FDA review modernization is the central regulatory reform frame in Supercharging a New FDA: Marty Makary on Science, Power & Patients. Marty Makary argues that the FDA should move faster without making safety performative: public rejection letters, priority reviews, one well-designed pivotal trial where appropriate, digital workflows, and less siloed agency structure are presented as tools for speed and transparency.

The concept sits beside Clinical Development Capability. A company still needs good trial design, endpoints, data, manufacturing, and evidence, but the regulator can either add friction through paperwork and silos or make evidence review more continuous and legible.

Key Claims

• The source frames approval delay as an active patient risk, not only as protection from unsafe drugs.
• Makary says the FDA should compete on speed and efficiency because global biotech competition makes slow domestic trial starts costly.
• Modernization includes internal culture, review structure, public transparency, and clinical-trial design rather than only faster deadlines.
• The strongest version of the claim depends on Post-Market Drug Surveillance: faster decisions are easier to justify if monitoring continues after approval.

Connections

• FDA and Marty Makary - agency and source speaker.
• Clinical Trial Continuity, Post-Market Drug Surveillance, Animal Testing Substitution, and Plausible Mechanism Pathway - reform components.
• Clinical Development Capability and CAR-T cell therapy - biotech execution and therapy contexts.
• Medical Dogma Trust Repair - public-trust frame that motivates more transparent review.